Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

Administration and Dosing of Tagraxofusp for BPDCN

Emanuele Angelucci

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

BPDCN: Current and Future Directions

Icahn School of Medicine at Mount Sinai

N. Pemmaraju

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Emerging Treatment Options for AML in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

A. Perl

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger Patien…

2024 ASCO® Annual Meeting Insights Hub

C. McMahon

Integrating Targeted Therapies in AML

Icahn School of Medicine at Mount Sinai

H. Kantarjian

Management of AML in Older Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

Current Treatment Landscape in BPDCN

Cristina Papayannidis

EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagra…

Insights from 2024 EHA Annual Meeting

E. Angelucci